A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Avelumab (Primary) ; Domatinostat (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms MERKLIN 1
- Sponsors 4SC
Most Recent Events
- 10 Mar 2022 This trial has been discontinued in Italy (End Date: 26 Oct 2021), according to European Clinical Trials Database record.
- 21 Nov 2021 This trial has been discontinued in Poland (End Date: 26 Oct 2021), according to European Clinical Trials Database record.
- 10 Nov 2021 Planned End Date changed from 1 Sep 2026 to 1 Sep 2025.